Career & Filing History
Every role Carl L. Gordon has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
Carl L. Gordon serves as Director of BlossomHill Therapeutics, Inc. (BLSM). Gordon has also held reporting roles at Scribe Therapeutics, Inc. (SCTX) and Compass Therapeutics, Inc. (CMPX). Gordon has reported 11 insider filings with the SEC since 2024. The most recent filing was in August 2026.
Every role Carl L. Gordon has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
BlossomHill Therapeutics, Inc. (BLSM)2 filingsScribe Therapeutics, Inc. (SCTX)2 filingsLatest filing:
Carl L. Gordon is Director of BlossomHill Therapeutics, Inc. (BLSM). 9 SEC Form 4 filings on record going back to 2024, most recently on 12 August 2026. Most recent open-market trade: bought $10.00M of BLSM on 12 August 2026. Lifetime open-market purchases: $25.00M. Lifetime open-market sales: $5.68M.
Every recent SEC Form 4 transaction Carl L. Gordon has reported, most recent first.
InsiderAlpha's records for Carl L. Gordon go back to 2024: 9 primary Form 4 filings, an average of 3.0 per year. The typical open-market purchase is $12.50M (2 buys totaling $25.00M). The largest single buy on record is $15.00M of SCTX in 2026. Sales side: 1 recorded sale totaling $5.68M, so the filing history runs buy-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Insiders who reported open-market trades in the last 12 months at the companies Carl L. Gordon files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Carl L. Gordon is a corporate insider, tracked as Director of BlossomHill Therapeutics, Inc. (BLSM). InsiderAlpha holds 9 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 2 open-market purchases ($25.00M) and 1 open-market sale ($5.68M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$BLSM BlossomHill Therapeutics, Inc.1.04M shares @ --
155.1K shares @ $4.00$620K
479.7K shares @ $4.00$1.92M
808.9K shares @ $4.00$3.24M
74.6K shares @ $3.60$269K
230.8K shares @ $3.60$831K
389.1K shares @ $3.60$1.40M
215.1K shares @ $3.20$688K
323.9K shares @ $3.20$1.04M